Elanco Animal Health Incorporated (NYSE:ELAN) is reporting third quarter earnings results on Friday 6th November 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 0.12 per share.
For the full year, analysts predict revenues of $ 3248.31 million, while looking forward to income of $ 0.55 per share.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 660.00 million ~ $ 710.00 million
Full Year 2020 topline are forecasted in a range of$ 3,000.00 million ~ $ 3,060.00 million, where as bottomline are predicted in a range of $ 1.09 ~ $ 1.16 per share
Click Here For More Historical Outlooks Of Elanco Animal Health Incorporated
Previous Quarter Performance
Elanco Animal Health Incorporated revealed income for the second quarter of $ 0.09 per share, from the revenue of $ 586.30 million. The quarterly earnings contracted 67.86 percent while revenues dropped 24.99 percent compared with the same quarter last year.
The consensus estimates are income of $ 0.06 per share from $ 589.43 million in revenue. The bottom line results beat street analysts by $ 0.03 or 50.00 percent, at the same time, top line results fell short of analysts by $ 3.13 million or 0.53 percent.
Stock Performance
Shares of Elanco Animal Health Incorporated traded up $ 0.87 or 2.74 percent on Thursday, reaching $ 32.58 with volume of 5.26 million shares. Elanco Animal Health Incorporated has traded high as $ 32.79 and has cracked $ 32.04 on the downward trend
According to the previous trading day, closing price of $ 32.58, representing a 109.03 % increase from the 52 week low of $ 15.17 and a 6.98 % decrease over the 52 week high of $ 34.09.
The company has a market capital of $ 15.37 billion and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Elanco Animal Health Incorporated will be hosting a conference call at 8:00 AM eastern time on 6th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.elanco.com
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production. It sells its products to third-party distributors; veterinarians; and food animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific.